Medication topics
Adalimumab articles covering Humira, biosimilars, anti-TNF therapy, safety, approvals, and IBD treatment decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
41 articles
Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...
Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.
Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.
Patients and clinicians are interested in whether combining two targeted biologic therapies can induce stronger endoscopic healing for people with difficult-to-treat Crohn's disease, and whether benefit can be maintained...
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
Some rare autoinflammatory disorders can look like IBD but need different diagnostic thinking. Recognizing systemic signs and checking serum zinc may lead to a correct diagnosis and targeted care.
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission,...
High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...
Injection site pain and local reactions can affect comfort and willingness to continue injectable biologic therapy.
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
Personalizing adalimumab dosing could reduce underexposure, treatment failure, and immunogenicity for people with IBD. Validated popPK models are a key step toward reliable model-informed precision dosing in clinical...
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.
This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Adalimumab, and Anti-TNF. Open the original article for the full details.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
